← Back to patent-cliff list
Pulrodemstat
Tier C — Watch / tradePulrodemstat
Celgene Corporation
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LSD1
Indications (approved)：Neoplasm, Prostate cancer, Small cell lung cancer, Non-Hodgkin lymphoma, Myeloid leukaemia
Regional status
US
Phase II
2020-07-14
EU
Phase II
2020-07-14
China
-
Japan
Discontinued
2016-08-31
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pulrodemstat?
Approved indications include: Neoplasm, Prostate cancer, Small cell lung cancer, Non-Hodgkin lymphoma, Myeloid leukaemia.
When does the Pulrodemstat patent expire?
No public expiry year is available for Pulrodemstat yet; this page updates once verified.
How do I get a quote for Pulrodemstat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06